Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aneurysm & intracranial embolization cases in Colorado: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 107 | 46% |
| 2020 | 0 | 104 | 48% |
| 2021 | 4 | 148 | 50% |
| 2022 | 1 | 121 | 53% |
| 2023 | 3 | 169 | 55% |
| 2024 | 6 | 214 | 57% |
| 2025 from claims | – | 263 213–309 | 57% |
| 2026 forecast | – | 296 232–372 | 56% |
| 2027 forecast | – | 326 241–430 | 56% |
| 2028 forecast | – | 358 253–494 | 57% |
| 2029 forecast | – | 394 268–564 | 57% |
| 2030 forecast | – | 433 284–642 | 57% |
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Colorado; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| Forecast, Medicare FFS | Inpatient |
|---|---|
| 2026 · ~300 | ~300 |
| 2027 · ~330 | ~330 |
| 2028 · ~360 | ~360 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 48 | 1,774+17%/yr | +17%/yr | 0.5 | 0% | 3,530 in 2030+12%/yr |
| Washington | 12 | 398+16%/yr | +16%/yr | 0.5 | 0% | 840 in 2030+13%/yr |
| Arizona | 12 | 342+14%/yr | +14%/yr | 0.5 | 0% | 770 in 2030+14%/yr |
| Nevada | 3 | 177+15%/yr | +15%/yr | 0.6 | 0% | 310 in 2030+9.8%/yr |
| Oregon | 2 | 108+11%/yr | +11%/yr | 0.3 | 0% | 150 in 2030+5.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| DBS & VNS | 5 | 282−2.4%/yr | −2.4%/yr | 0.61.8× | 14% | 540 in 2030+12%/yr |
| Stroke thrombectomy | 7 | 194+4.9%/yr | +4.9%/yr | 0.41.0× | 0% | 180 in 2030−1.5%/yr |
Aneurysm & intracranial embolization in every state, and its device makers · Every procedure market in Colorado · Every state · Compare with California
Medtronic leads with 56% of company spending on these surgeons in 2025, +21 pts on 2024.
In 2025, 8 companies reported engagement with Colorado’s surgeons worth $101K in consulting, speaking, meals and travel tied to these products, about $17K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.